STAT

AUGUST 30, 2024

… Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment , STAT writes. of those who received placebo.

Hospitals 282

Hospitals Labelling 282

Pharmaceutical Technology

MARCH 22, 2023

Hospital clinicians should never have to decide whether our +RFID products are compatible; medications should work effortlessly in whatever system a hospital wants to purchase. RFID is an important facet of smart labelling and its evolution, but not the only one. That is where GS1 standards come in,” says Volpe.

Labelling 105

Labelling Data Entry Communication Hospitals 105

Express Pharma

JANUARY 19, 2025

This study consists of a 36-week treatment phase, followed by a 16-week open-label extension. Zydus Lifesciences announced that it has received USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS).

Clinical Pharmacology 111

Clinical Pharmacology Labelling Medical Schools Drug Development 111

Pharmacy Times

NOVEMBER 8, 2024

Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.

Compounding 37

Compounding Labelling Hospitals 37

Pharmacy Joe

JUNE 7, 2023

In this episode, I’ll discuss torsemide vs furosemide for symptoms and quality of life among patients hospitalized for heart failure. Episode 824: Torsemide vs Furosemide – Which Is Better For Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure? appeared first on Pharmacy Joe.

Hospitals 59

Hospitals Inpatient Labelling 59

ALiEM - Pharm Pearls

OCTOBER 14, 2023

Take the AIR Respiratory Module at ALiEMU Interested in taking the AIR quiz for fun or asynchronous (Individualized Interactive Instruction) credit? Please go to the above link. You will need to create a free, 1-time login account.

Labelling 169

Labelling Hospitals 169

Proxsys Rx

MAY 3, 2023

340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post , for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Novartis is sending a variation of the same letter to hospitals.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Documentation Labelling 52

Pharmacy Times

MAY 9, 2023

Dapagliflozin was established as the first SGLT2 inhibitor that demonstrated a mortality benefit for cardiovascular death from heart failure.

Labelling 49

Labelling Hospitals 49

pharmaphorum

MARCH 3, 2022

The findings – published today in the journal Nature Medicine – come after Jardiance was approved for chronic heart failure with reduced ejection fraction (HFrEF) last year, with the label expanded to include patients with heart failure with preserved ejection fraction (HFpEF) last month. It has been used to treat type 2 diabetes since 2014.

Labelling 98

Labelling Diabetes Hospitals 98

pharmaphorum

SEPTEMBER 16, 2020

The phase 3 open-label trial will test the cocktail in patients hospitalised with COVID-19 and will compare the effects of adding the antibody cocktail REGN-COV2 to the usual standard-of-care versus standard-of-care on its own. The post Regeneron tests COVID-19 antibody therapy in UK’s RECOVERY trial appeared first on.

Hospitals 98

Hospitals Labelling Immunity Immunization 98

Pharmacy Joe

NOVEMBER 10, 2021

In this episode, I’ll discuss colchicine in patients admitted to hospital with COVID-19. Episode 660: Does colchicine work in patients admitted to hospital with COVID-19? mg orally 12 hours later and twice daily thereafter for 10 days or until hospital discharge. appeared first on Pharmacy Joe.

Hospitals 40

Hospitals Inpatient Dosage Labelling 40

FDA Law Blog: Biosimilars

AUGUST 7, 2024

But recently, a new challenge was filed in the District Court for the District of Columbia questioning whether modifications to labeling as a result of patent protections—beyond the mere omission of language—are permissible under the section viii carve-out requirements.

Labelling 59

Labelling Hospitals 59

Pharmacy Is Right For Me

OCTOBER 21, 2022

This saved the Nuclear Pharmacies money and time usually spent on training Hospital and Retail pharmacists who left those settings for Nuclear. During the week, I work at the hospital from morning to afternoon. What does a typical workday look like for you?

Hospitals 130

Hospitals Labelling Vaccines Drug Development 130

Pharmaceutical Technology

MAY 29, 2023

Lexicon senior vice president and chief medical officer Dr Craig Granowitz said: “With today’s FDA approval, Inpefa is now a valuable option for physicians to consider when treating patients transitioning out of the hospital and working to break the cycle of repeated hospitalisation.”

Labelling 98

Labelling Diabetes Hospitals 98

European Pharmaceutical Review

DECEMBER 13, 2024

This authorises a novel CE-labelled needle for intravitreal injection. The European Medicines Agency (EMA) has approved Roche’s Vabysmo (faricimab) prefilled syringe (PFS) as the EUs first and only bispecific antibody prefilled syringe for retinal conditions causing vision loss.

Diabetes 97

Diabetes Labelling Hospitals 97

Pharmacy Joe

OCTOBER 3, 2021

In this episode, I’ll discuss whether albumin infusions improve outcomes in hospitalized patients with decompensated cirrhosis. Episode 649: Do albumin infusions improve outcomes in hospitalized patients with decompensated cirrhosis? Almost 800 hospitalized cirrhotic patients with albumin levels less than 3g/dL were enrolled.

Hospitals 40

Hospitals Inpatient Labelling 40

Pharmacy Joe

AUGUST 16, 2023

By predicting this need in advance, calculating doses, preparing and labeling syringes, the pharmacist can also enhance medication safety and free up the rest of the care team to remain hands-on with the patient ensuring adequate pre-oxygenation, IV access, and supportive care.

Hospitals 98

Hospitals Inpatient Labelling 98

Pharmaceutical Technology

JULY 20, 2022

While the label expansion will likely increase avenues for patients to access the antiviral, Ganio adds one caveat: due to burnout and turnover seen across the healthcare field, including pharmacy staff, there are going to be sites that just don't have the resources to dedicate a pharmacist to do some of this work.

Labelling 111

Labelling Community Pharmacies Medical Records Communication 111

Pharmaceutical Technology

SEPTEMBER 5, 2022

Simpson alleged in a lawsuit filed in the District of New Jersey that Bayer paid kickbacks to physicians and hospitals to prompt them to use Trasylol and Avelox. Simpson also alleged that the company sold these drugs for off-label usages that were not acceptable and essential.

Labelling 105

Labelling Hospitals 105

European Pharmaceutical Review

JULY 26, 2023

The oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor is the first type 2 diabetes medicine to include cardiovascular death risk reduction data for patients with type 2 diabetes and cardiovascular disease in its label in several countries.

Diabetes 98

Diabetes Labelling Hospitals 98

pharmaphorum

DECEMBER 15, 2022

Boehringer did not carry out a dedicated clinical trial to show the benefit of Ofev in this less severely affected population, but provided subgroup analyses from two earlier studies – INPULSIS and TOMORROW – plus open-label extensions. The post NICE backs use of Boehringer’s Ofev in IPF from diagnosis appeared first on.

Labelling 105

Labelling Hospitals 105

European Pharmaceutical Review

JUNE 10, 2024

New five-year data from Genentech (a member of the Roche Group)’s open-label extension of the pivotal Phase II FIREFISH study confirm the sustained efficacy and safety of Evrysdi ® (risdiplam) in children with Type 1 spinal muscular atrophy (SMA). What did the FIREFISH extension study find?

Labelling 98

Labelling Hospitals 98

pharmaphorum

OCTOBER 16, 2020

Gilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in a large global trial, casting doubt on previous supportive study findings. According to the study the regimens have little or no effect on length of hospital stay or 28-day mortality, the WHO said.

Hospitals 76

Hospitals Labelling Compounding 76

European Pharmaceutical Review

JUNE 28, 2022

The Phase III Asclepios I/II trials and the Alithios open-label extension from Novartis , showed that earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study.

Labelling 98

Labelling Hospitals 98

pharmaphorum

SEPTEMBER 18, 2020

But the findings of the latest phase 3 study, EMPACTA, could change that after Roche said it plans to share results with the FDA and other regulators to get its label expanded on the basis of the latest results. The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the placebo arm.

Labelling 97

Labelling Immunity Immunization Hospitals 97

pharmaphorum

SEPTEMBER 16, 2020

Remdesivir was filed for approval in the US as Veklury after being cleared for emergency use in May based on data from the ACTT-1 trial showing that it could shorten hospital recovery time from around 15 days to 11 days.

Labelling 111

Labelling Hospitals 111

The Honest Apothecary

APRIL 24, 2023

A condition known as “Opioid Induced Hyperalgesia” or OHA has been reported enough times now that the FDA is requiring an update to all the labeling of all opioids to reflect this potential risk. “After starting to use the new version, the patient experienced 3 seizures, which led to her being admitted to the hospital.

Compounding 97

Compounding Labelling Hospitals 97

RX Note

JULY 2, 2023

Introduction American Hospital Formulary Service Drug Information (AHFS DI) from the American Society of Health-System Pharmacists (ASHP) is a comprehensive source of drug information for health professionals with therapeutic guidelines and off-label uses.

Labelling 40

Labelling Hospitals 40

pharmaphorum

FEBRUARY 3, 2021

But after an initial loading phase it cuts the number of hospital visits required to get the same clinical effect, with a dosing period of up to 12 weeks. More than half of patients were maintained on 12-weekly dosing regimens after the loading phase in a 48-week trial, Novartis pointed out.

Labelling 98

Labelling Hospitals 98

Pharma Pathway

FEBRUARY 14, 2023

Candidates from OSD and Injectibels can attend interview.

People Management 64

People Management Labelling Hospitals 64

RX Note

MARCH 18, 2023

Also, it forms the hospital/clinical drug formulary foundation for all government healthcare facilities at Malaysia. Not all hospital drugs are listed in MOHMF. Not all drugs in MOHMF are available in our hospital/clinic. Government should initiate a local hospital/clinic drug formulary mobile application instead.

Hospitals 52

Hospitals Dosage Labelling 52

European Pharmaceutical Review

NOVEMBER 28, 2022

The comparative, randomised, open-label clinical trial evaluated the drug’s short- and long-term efficacy, safety and tolerability. Patients treated with SPRAVATO ® achieved greater rates of remission at Week eight: 27.1 percent versus 17.6 percent, respectively; p=0.003) compared to those given quetiapine XR.

Labelling 98

Labelling Hospitals 98

Pharmaceutical Technology

JUNE 21, 2023

Ketarx will be marketed under the FDA-approved label of ketamine and in dosages that include 10mg/ml, 50mg/ml and 100mg/ml, with the option to boost the concentration and ready-to-administer applications. PharmaTher and Vitruvias Therapeutics have entered a collaboration deal to commercialise PharmaTher’s Ketarx (racemic ketamine) in the US.

Hospitals 52

Hospitals Dosage Labelling 52

European Pharmaceutical Review

SEPTEMBER 15, 2022

At week 24, the open-label extension (Period 2) began, and all patients were treated with Skyrizi. New data from the open-label extension period revealed that at 100 weeks, 64 and 57 percent of patients initially treated with Skyrizi achieved ACR20 response in KEEPsAKE 1 and 2, respectively. . The two studies are ongoing. .

Labelling 94

Labelling Immunity Immunization Hospitals 94

pharmaphorum

OCTOBER 22, 2020

Phase 3 trials are expected to start in Q1 2021, and will test the drug outside of the hospital setting. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.”

Hospitals 66

Hospitals Biosimilars Labelling 66

Pharmacy Joe

OCTOBER 22, 2023

In this episode, I’ll discuss an article about cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection. The authors concluded: Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of AKI or death.

Hospitals 52

Hospitals Labelling Inpatient 52

Pharmacy Joe

OCTOBER 22, 2023

In this episode, I’ll discuss an article about cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection. The authors concluded: Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of AKI or death.

Hospitals 52

Hospitals Labelling Inpatient 52